Purgo Pipeline
The Purgo Pouch is designed to address the inherent limitations of systemic drug delivery by providing localized, rate-controlled drug administration via passive diffusion. This platform approach enables sustained therapeutic exposure at the site of need while minimizing systemic burden. Purgo is actively evaluating the broader applicability of the technology across multiple indications, including infection, pain management, oncology, and beyond.
Surgical Site Infection
By the Numbers in the U.S.
Surgical Site Infections Cost the U.S. Healthcare System
$10 BILLION ANNUALLY
And Impact Over 300,000 Patients a Year
#1
Cause of Healthcare Acquired Infections
9,000
Number of U.S. Patients that Die From SSI Annually
#1
Cause of Readmissions After Surgery
9.7
Average Number of Days in Hospital Due to SSI
Purgo Use Case Pathway
Product/Platform
Discovery
Pre-clinical
Phase 1
Orthopedic surgical site infection – treatment
Manage surgical site infections that affect bone such as in open fractures
Orthopedic surgical site infection – prophylaxis
Prevent surgical site infections from developing in, for example, open fractures
General surgical site infection – treatment
Manage infection present in soft tissue spaces
General surgical site infection – prophylaxis
Prevent infection from developing in soft tissue spaces
Pain management – post-operative
Provide post-surgical pain relief via sustained local anesthetic delivery
Oncology – solid tumors
Target tumors with local delivery of multimodal synergistic small molecule and/or antibody combinations (reduced systemic toxicity)
Bone growth and fracture healing – expedite
Locally deliver bone growth agents (bone morphogenetic protein) expediting fracture healing and bone growth in other applications